open access

Vol 65, No 2 (2014)
Original papers
Published online: 2014-05-06
Submitted: 2014-05-06
Accepted: 2014-05-06
Get Citation

Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients?

Krzysztof Strojek, Juta Górska, Dominika Rokicka, Aleksandra Szymborska-Kajanek, Marta Wróbel, Łukasz Sędek, Tomasz Szczepański
DOI: 10.5603/EP.2014.0011
·
Endokrynologia Polska 2014;65(2):78-82.

open access

Vol 65, No 2 (2014)
Original papers
Published online: 2014-05-06
Submitted: 2014-05-06
Accepted: 2014-05-06

Abstract

Introduction: Dipeptidil peptidase 4 inhibitors (DPP-4) are a group of antihyperglycemic agents. DPP-4 is an enzyme expressed on lymphocyte surface as co-stimulatory molecule in activation processes. The aim was to assess lymphocyte subpopulations initially and after 14 days of treatment with DPP-4 inhibitors sitagliptin, saxagliptin and vildagliptin.

Material and methods: The study was conducted in three groups 10 subjects each, of type 2 diabetic patients. In subjects studied an initial tests followed by repeated ones after 14 days of treatment with sitagliptin, saxagliptin, and vildagliptin in therapeutic doses were performed. Baseline test as well as lymphocyte subpopulations (total T cells, and T-cell subsets CD4+, CD8+, CD26+, CD45RA+, CD45RO+, CD4+/CD25+) using 7-colour flow cytometry method were performed.

Results: In patients receiving sitagliptin no significant increase in lymphocyte subpopulations were observed. In patients who received vildagliptin significant increase of total T-cells (p < 0.05); in patients treated with saxagliptin significant (p < 0.05) though mild increased percentage of total T-cells and CD4+, CD26+, CD45RO+ subsets were found.

Conclusions: The study showed mild but significant increase of several T-cell subsets after treatment with saxagliptin and vildagliptin with non significant elevation after treatment with sitagliptin. It seems that changes are not expressed enough to have a clinical impact. (Endokrynol Pol 2014; 65 (2): 78–82)

Abstract

Introduction: Dipeptidil peptidase 4 inhibitors (DPP-4) are a group of antihyperglycemic agents. DPP-4 is an enzyme expressed on lymphocyte surface as co-stimulatory molecule in activation processes. The aim was to assess lymphocyte subpopulations initially and after 14 days of treatment with DPP-4 inhibitors sitagliptin, saxagliptin and vildagliptin.

Material and methods: The study was conducted in three groups 10 subjects each, of type 2 diabetic patients. In subjects studied an initial tests followed by repeated ones after 14 days of treatment with sitagliptin, saxagliptin, and vildagliptin in therapeutic doses were performed. Baseline test as well as lymphocyte subpopulations (total T cells, and T-cell subsets CD4+, CD8+, CD26+, CD45RA+, CD45RO+, CD4+/CD25+) using 7-colour flow cytometry method were performed.

Results: In patients receiving sitagliptin no significant increase in lymphocyte subpopulations were observed. In patients who received vildagliptin significant increase of total T-cells (p < 0.05); in patients treated with saxagliptin significant (p < 0.05) though mild increased percentage of total T-cells and CD4+, CD26+, CD45RO+ subsets were found.

Conclusions: The study showed mild but significant increase of several T-cell subsets after treatment with saxagliptin and vildagliptin with non significant elevation after treatment with sitagliptin. It seems that changes are not expressed enough to have a clinical impact. (Endokrynol Pol 2014; 65 (2): 78–82)

Get Citation

Keywords

diabetes type 2; DPP-4 inhibitors; lymphocyte subpopulations

About this article
Title

Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients?

Journal

Endokrynologia Polska

Issue

Vol 65, No 2 (2014)

Pages

78-82

Published online

2014-05-06

DOI

10.5603/EP.2014.0011

Bibliographic record

Endokrynologia Polska 2014;65(2):78-82.

Keywords

diabetes type 2
DPP-4 inhibitors
lymphocyte subpopulations

Authors

Krzysztof Strojek
Juta Górska
Dominika Rokicka
Aleksandra Szymborska-Kajanek
Marta Wróbel
Łukasz Sędek
Tomasz Szczepański

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl